Insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Mereo Biopharma Group Plc (MREO) since 2024 are shown in Table 1 and Table 2. Table 1 shows the monthly insider trading data of Mereo Biopharma Group Plc. Table 2 shows the detailed insider transactions. This company's CIK number is 1719714.
Total stock buying since 2024: $0.
Total stock sales since 2024: $3,079,684.
Total stock option exercises since 2024: $610,088.
| Insider Buying | Insider Sales | Option Exercises | ||||
|---|---|---|---|---|---|---|
| Year | Shares | Value | Shares | Value | Shares | Value |
| 2024 | 0 | $0 | 796,933 | $3,079,684 | 1,441,060 | $610,088 |
| Trading Period | Insider Buying | Insider Sales | Option Exercises | |||
|---|---|---|---|---|---|---|
| year-month | Shares | Value | Shares | Value | Shares | Value |
| 2024-09 | 0 | $0 | 312,128 | $1,342,872 | 567,993 | $167,291 |
| 2024-08 | 0 | $0 | 105,244 | $466,230 | 105,244 | $239,956 |
| 2024-06 | 0 | $0 | 279,129 | $972,802 | 599,490 | $0 |
| 2024-05 | 0 | $0 | 100,432 | $297,780 | 168,333 | $202,841 |
| Trade Date | Insider Name | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2024-09-13 | Hughes-wilson Alexandra (See Remarks) | Sale | 100,312 | 4.22 | 423,416 |
| 2024-09-13 | Fox Christine Ann (Chief Financial Officer) | Sale | 19,158 | 4.22 | 80,865 |
| 2024-09-13 | Sermon Charles (General Counsel) | Sale | 20,946 | 4.22 | 88,413 |
| 2024-09-13 | Lewicki John A. (Chief Scientific Officer) | Sale | 10,937 | 4.22 | 46,165 |
| 2024-09-13 | Scots-knight Denise (Chief Executive Officer) | Sale | 60,046 | 4.22 | 253,454 |
| 2024-09-12 | Hughes-wilson Alexandra (See Remarks) | Sale | 47,798 | 4.47 | 213,800 |
| 2024-09-12 | Fox Christine Ann (Chief Financial Officer) | Sale | 9,128 | 4.47 | 40,829 |
| 2024-09-12 | Sermon Charles (General Counsel) | Sale | 9,980 | 4.47 | 44,640 |
| 2024-09-12 | Lewicki John A. (Chief Scientific Officer) | Sale | 5,212 | 4.47 | 23,313 |
| 2024-09-12 | Scots-knight Denise (Chief Executive Officer) | Sale | 28,611 | 4.47 | 127,977 |
| 2024-09-11 | Hughes-wilson Alexandra (See Remarks) | Option Ex | 208,333 | .80 | 167,291 |
| 2024-09-11 | Fox Christine Ann (Chief Financial Officer) | Option Ex | 60,000 | .00 | 0 |
| 2024-09-11 | Sermon Charles (General Counsel) | Option Ex | 65,600 | .00 | 0 |
| 2024-09-11 | Lewicki John A. (Chief Scientific Officer) | Option Ex | 46,000 | .00 | 0 |
| 2024-09-11 | Scots-knight Denise (Chief Executive Officer) | Option Ex | 188,060 | .00 | 0 |
| 2024-08-22 | Pakianathan Deepika | Sale | 105,244 | 4.43 | 466,230 |
| 2024-08-22 | Pakianathan Deepika | Option Ex | 105,244 | 2.28 | 239,956 |
| 2024-06-26 | Hughes-wilson Alexandra (See Remarks) | Sale | 22,968 | 3.39 | 77,930 |
| 2024-06-26 | Fox Christine Ann (Chief Financial Officer) | Sale | 29,439 | 3.39 | 99,886 |
| 2024-06-26 | Sermon Charles (General Counsel) | Sale | 32,187 | 3.39 | 109,210 |
| 2024-06-26 | Lewicki John A. (Chief Scientific Officer) | Sale | 16,808 | 3.39 | 57,029 |
| 2024-06-26 | Scots-knight Denise (Chief Executive Officer) | Sale | 92,273 | 3.39 | 313,082 |
| 2024-06-25 | Hughes-wilson Alexandra (See Remarks) | Sale | 10,134 | 3.69 | 37,434 |
| 2024-06-25 | Fox Christine Ann (Chief Financial Officer) | Sale | 12,990 | 3.69 | 47,985 |
| 2024-06-25 | Sermon Charles (General Counsel) | Sale | 14,202 | 3.69 | 52,462 |
| 2024-06-25 | Lewicki John A. (Chief Scientific Officer) | Sale | 7,416 | 3.69 | 27,394 |
| 2024-06-25 | Scots-knight Denise (Chief Executive Officer) | Sale | 40,712 | 3.69 | 150,390 |
| 2024-06-21 | Hughes-wilson Alexandra (See Remarks) | Option Ex | 60,000 | .00 | 0 |
| 2024-06-21 | Fox Christine Ann (Chief Financial Officer) | Option Ex | 90,000 | .00 | 0 |
| 2024-06-21 | Sermon Charles (General Counsel) | Option Ex | 98,400 | .00 | 0 |
| 2024-06-21 | Lewicki John A. (Chief Scientific Officer) | Option Ex | 69,000 | .00 | 0 |
| 2024-06-21 | Scots-knight Denise (Chief Executive Officer) | Option Ex | 282,090 | .00 | 0 |
| 2024-05-22 | Hughes-wilson Alexandra (See Remarks) | Sale | 100,432 | 2.96 | 297,780 |
| 2024-05-22 | Hughes-wilson Alexandra (See Remarks) | Option Ex | 168,333 | 1.21 | 202,841 |
Insider trading activities including stock purchases, stock sales, and option exercises of MREO listed in the above tables cannot be completely guaranteed as to their accuracy. For more insider trading information of Mereo Biopharma Group Plc (symbol MREO, CIK number 1719714) see the Securities and Exchange Commission (SEC) website.